CONTINGENT PAYMENT (Details Narrative)	9 Months Ended
CONTINGENT PAYMENT (Details Narrative)	Sep. 30, 2025 USD ($)
CONTINGENT PAYMENT
Net sales and profit sharing	$ 400,000
Upfront purchase price	$ 400,000
Seller for purchase of assets description	on March 4, 2025, the Company shall pay upfront purchase price of $400,000 via Seller's retention, until such amounts equal $400,000 of 50% of the Net Sales (as defined in the APA) of Lucemyra and 50% of the Net Distributable Profits (as defined in the APA) of the generic version of Lucemyra. The Company shall also pay to the Seller a royalty equal to 3% of the Net Sales of Lucemyra and 3% of the Net Distributable Profits of the generic version of Lucemyra on a calendar quarter basis. Royalty payments shall commence on the date of the acquisition and shall continue for a period of 5 years following the date of the acquisition
Royalty payments period	5 years